Open Access

Erratum to: Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients

  • Felix Poppelaars1Email authorView ORCID ID profile,
  • Mariana Gaya da Costa1,
  • Stefan P. Berger1,
  • Solmaz Assa2,
  • Anita H. Meter-Arkema1,
  • Mohamed R. Daha1, 3,
  • Willem J. van Son1,
  • Casper F. M. Franssen1 and
  • Marc A. J. Seelen1
Contributed equally
Journal of Translational Medicine201614:245

https://doi.org/10.1186/s12967-016-1004-8

Published: 24 August 2016

The original article was published in Journal of Translational Medicine 2016 14:236

Erratum to: J Transl Med (2016) 14:236 DOI:10.1186/s12967-016-0995-5

Unfortunately, the original version of this article [1] contained errors in the main text and in Tables 2 and 3. Tables 2 and 3 were included incorrectly. The correct Tables 2 and 3 have been updated in the original article and are also included correctly in this erratum.
Table 2

Baseline characteristics of hemodialysis patients presented as groups according to MBL levels

 

Patients

P* < 0.001

R

P#

All (n = 107)

MBL low 319 < ng/mL (n = 26)

MBL high 319 ≥ ng/mL (n = 81)

MBL range (ng/mL)

821 [319–1477]

98 [33–146]

1290 [671–1848]

Demographics

Age, years

62.5 ± 15.6

65.3 ± 12.1

61.56 ± 16.6

0.3

−0.26

0.007

Male gender, n (%)

71 (66)

17 (65)

54 (67)

1.0

  

Current diabetes, n (%)

25 (24)

9 (35)

16 (20)

0.2

  

Hypertension, n (%)

85 (84)

22 (88)

63 (83)

0.8

  

Cardiovascular history, n (%)

26 (25)

9 (35)

15 (19)

0.1

  

BMI, kg/m2

25.8 ± 4.4

27.0 ± 4.5

25.4 ± 4.4

0.1

−0.03

0.8

Hemodialysis

Dialysis vintage, months

25.5 [8.5–52.3]

18.2 [7.0–47.7]

32.8 [9.1–53.3]

0.2

−0.01

0.9

Primary renal disease, n (%)

Hypertension

18 (17)

4 (15)

14 (17)

1.0

  

Diabetes

14 (13)

5 (19)

9 (11)

0.3

  

ADPKD

13 (12)

3 (12)

10 (12)

1.0

  

FSGS

9 (8)

4 (15)

5 (6)

0.2

  

IgA nephropathy

4 (4)

0 (0)

4 (5)

0.6

  

Chronic pyelonephritis

3 (3)

0 (0)

3 (4)

1.0

  

Glomerulonephritis

13 (12)

2 (8)

11 (14)

0.7

  

Other diagnoses

16 (16)

6 (23)

10 (12)

0.2

  

Unknown

17 (16)

2 (8)

15 (19)

0.2

  

Ultrafiltration volume, L

2.55 ± 0.78

2.54 ± 0.82

2.56 ± 0.78

0.9

−0.01

0.9

Ultrafiltration rate, mL/kg/h

8.56 ± 2.63

7.81 ± 2.39

8.80 ± 2.67

0.1

0.04

0.7

Systolic blood pressure

Predialysis, mmHg

140.4 ± 25.1

144.7 ± 26.4

139.1 ± 24.7

0.3

−0.17

0.08

Postdialysis, mmHg

131.8 ± 25.6

136 ± 24.3

130.4 ± 26.0

0.4

−0.24

0.02

Heart rate

Predialysis, bpm

73 [63–82]

71 [62–82]

74 [64–82]

0.3

0.11

0.3

Postdialysis, bpm

79 [69–87]

75 [65–86]

79 [69–88]

0.4

0.13

0.2

Kidney transplant, n (%)

21 (20)

4 (15)

17 (21)

0.8

  

Laboratory measurements

Hematocrit, %

34.9 ± 3.8

34.5 ± 4.1

35.0 ± 3.7

0.6

0.04

0.7

HbAlc, mmol/mol

5.68 ± 0.98

5.80 ± 0.97

5.63 ± 0.98

0.5

−0.15

0.2

Albumin, g/L

39 [37–42]

39 [37–42]

39 [37–42]

0.9

0.01

0.9

pH

7.37 [7.34–7.39]

7.37 [7.32–7.39]

7.37 [7.34–7.39]

0.7

0.05

0.6

Calcium, mmol/L

2.31 ± 0.16

2.31 ± 0.15

2.32 ± 0.16

0.9

0.03

0.7

Phosphate, mmol/L

1.67 ± 0.53

1.82 ± 0.47

1.65 ± 0.54

0.2

−0.00

0.9

hsCRP, mg/L

6.7 [2.8–10.9]

6.1 [1.4–12.0]

6.7 [3.0–10.9]

0.7

0.10

0.3

Medication

Aspirin, n (%)

57 (54)

11 (42)

46 (64)

0.3

  

Calcium channel blockers, n (%)

14 (13)

3 (12)

11 (14)

1.0

  

β-Blocker, n (%)

61 (57)

18 (69)

43 (53)

0.2

  

ACE inhibitor, n (%)

10 (10)

3 (12)

7 (9)

0.7

  

AT2-receptor antagonists, n (%)

14 (13)

2 (8)

12 (15)

0.5

  

Statin, n (%)

20 (19)

5 (19)

15 (19)

1.0

  

Diuretics, n (%)

8 (8)

3 (12)

5 (6)

0.4

  

Italic values used to show which statistical testing was significant (below 0.05)

Data are presented as mean ± SD or median [IQR]

BMI body mass index, ADPKD autosomal dominant polycystic kidney disease, FSGS focal segmental glomerulosclerosis, HDA1c hemoglobin A1c, pH potential hydrogen, hsCRP high sensitive C-relative protein, ACE inhibitor angiotensin-converting-enzyme inhibitor, AT2 receptor antagonists Angiotensin II receptor antagonists

P* indicates P value for the difference in baseline characteristics between the MBL groups, tested by Student’s t test or Mann–Whitney U test for continuous variables and with χ2 test for categorical variables; R indicates Spearman correlation coefficient between MBL levels and the baseline characteristic; P# indicates the corresponding P value

Table 3

Associations of MBL levels with cardiovascular events and cardiac events in 107 chronic hemodialysis patients

 

Low MBL

Log MBL continuous

HR

95 % CI

P

HR (per SD)

95 % CI

P

Cardiovascular events

 Model 1

2.64

1.36–5.13

0.004

0.64

0.46–0.90

0.01

 Model 2

2.75

1.39–5.44

0.004

0.61

0.43–0.88

0.008

 Model 3

2.94

1.45–5.94

0.003

0.61

0.42–0.89

0.01

 Model 4

3.55

1.70–7.40

0.001

0.58

0.40–0.84

0.004

 Model 5

3.98

1.88–8.42

<0.001

0.56

0.38–0.81

0.002

Cardiac events

 Model 1

2.60

1.10–6.18

0.03

0.71

0.46–1.10

0.1

 Model 2

2.49

1.04–5.96

0.04

0.73

0.46–1.16

0.2

 Model 3

2.65

1.08–6.55

0.03

0.74

0.47–1.18

0.2

 Model 4

3.82

1.48–9.87

0.006

0.62

0.38–1.01

0.06

 Model 5

3.96

1.49–10.54

0.006

0.59

0.35–0.98

0.04

Model 1: crude

Model 2: adjusted for age and gender

Model 3: adjusted for model 2 plus ultrafiltration volume and dialysis vintage

Model 4: adjusted for model 3 plus cardiovascular history, diabetes and post-HD systolic blood pressure

Model 5: adjusted for model 4 plus hsCRP

Data are presented as hazard ratio (HR) plus 95 % confidence interval (CI) according to the cut-off of MBL and per standard deviation (SD) MBL increase

Italic values used to show which statistical testing was significant (below 0.05)

MBL mannose-binding lectin, HD hemodialysis, hsCRP high sensitive C-reactive protein

Additionally, the following section has been corrected:

However, after adjustment MBL for these confounders levels remained associated with cardiovascular events, indicating a direct and independent effect of MBL on cardiovascular risk.

Should read:

However, after adjustment for these confounders, MBL levels remained associated with cardiovascular events, indicating a direct and independent effect of MBL on cardiovascular risk.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen
(2)
Department of Cardiology, University Medical Center Groningen, University of Groningen
(3)
Department of Nephrology, Leiden University Medical Center, University of Leiden

Reference

  1. Poppelaars F, Gaya da Costa M, Berger SP, Assa S, Meter-Arkema AH, Daha MR, van Son WJ, Franssen CFM, Seelen MAJ. Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients. J Transl Med. 2016;14:236. doi:10.1186/s12967-016-0995-5.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2016

Advertisement